Effects of COX-2 inhibitor on growth of human gastric cancer cells and its relation to hepatocyte growth factor

Cancer Letters

Volumn 239, Issue 2, 2006, Pages 263-270

  Chen, Jen Hao ^a,b   Wu, Chew Wun ^a,b   Kao, Hwa Li ^a   Chang, Hwey May ^a   Li, Anna F Y ^a   Liu, Tsung Yun ^a,b   Chi, Chin Wen ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

c Met HGFR; COX 2; Gastric cancer; HGF; PGE2

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN; SCATTER FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN BINDING; STOMACH CANCER; STOMACH MUCOSA; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; HEPATOCYTE GROWTH FACTOR; HUMANS; MICE; MICE, SCID; PROTO-ONCOGENE PROTEINS C-MET; STOMACH NEOPLASMS;

EID: 33745660109     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.08.026     Document Type: Article

References (41)

1. Jones M.K., Sasaki E., Halter F., Pai R., Nakamura T., Arakawa T., et al. HGF triggers activation of the COX-2 gene in rat gastric epithelial cells: action mediated through the ERK2 signaling pathway. Fed. Am. Soc. Exp. Biol. J. 13 (1999) 2186-2194
2. Nakamura T., Teramoto H., and Ichihara A. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc. Natl Acad. Sci. USA 83 (1986) 6489-6493
3. Tajima H., Matsumoto K., and Nakamura T. Regulation of cell growth and motility by hepatocyte growth factor and receptor expression in various cell species. Exp. Cell Res. 202 (1992) 423-431
4. Liu S.I., Chi C.W., Lui W.Y., Mok K.T., Wu C.W., and Wu S.N. Correlation of hepatocyte growth factor-induced proliferation and calcium-activated potassium current in human gastric cancer cells. Biochim. Biophys. Acta 1368 (1998) 256-266
5. Rosen E.M., Carley W., and Goldberg I.D. Scatter factor regulates vascular endothelial cell motility. Cancer Invest. 8 (1990) 647-650
6. Baatar D., Jones M.K., Pai R., Kawanaka H., Szabo I.L., Moon W.S., et al. Selective cyclooxygenase-2 blocker delays healing of esophageal ulcers in rats and inhibits ulceration-triggered c-Met/hepatocyte growth factor receptor induction and extracellular signal-regulated kinase 2 activation. Am. J. Pathol. 160 (2002) 963-972
7. Niki M., Isozaki H., Toyoda M., Ishibashi T., Fujii K., Nomura E., et al. Serum human hepatocyte growth factor (hHGF) is elevated in patients with metastatic gastric carcinoma. Hepatogastroenterology 46 (1999) 568-573
8. Han S.U., Lee J.H., Kim W.H., Cho Y.K., and Kim M.W. Significant correlation between serum level of hepatocyte growth factor and progression of gastric carcinoma. World J. Surg. 23 (1999) 1176-1180
9. Wu C.W., Chi C.W., Su T.L., Liu T.Y., Lui W.Y., and P'Eng F. Serum hepatocyte growth factor level associate with gastric cancer progression. Anticancer Res. 18 (1998) 3657-3659
10. Wu C.W., Li A.F., Chi C.W., Chung W.W., Liu T.Y., Lui W.Y., et al. Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol. Rep. 5 (1998) 817-822
11. Elder D.J., Halton D.E., Hague A., and Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin. Cancer Res. 3 (1997) 1679-1683
12. DeWitt D.L. Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim. Biophys. Acta 1083 (1991) 121-134
13. Vane J. Towards a better aspirin. Nature 367 (1994) 215-216
14. Kujubu D.A., Fletcher B.S., Varnum B.C., Lim R.W., and Herschman H.R. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. 266 (1991) 12866-12872
15. Hla T., and Neilson K. Human cyclooxygenase-2 cDNA. Proc. Natl Acad. Sci. USA 89 (1992) 7384-7388
16. Crofford L.J., Wilder R.L., Ristimaki A.P., Sano H., Remmers E.F., Epps H.R., et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J. Clin. Invest. 93 (1994) 1095-1101
17. Smalley W.E., and DuBois R.N. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv. Pharmacol. 39 (1997) 1-20
18. Karnes Jr. W.E., Shattuck-Brandt R., Burgart L.J., DuBois R.N., Tester D.J., Cunningham J.M., et al. Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res. 58 (1998) 5473-5477
19. Farrow D.C., Vaughan T.L., Hansten P.D., Stanford J.L., Risch H.A., Gammon M.D., et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers Prev. 7 (1998) 97-102
20. Ristimaki A., Honkanen N., Jankala H., Sipponen P., and Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57 (1997) 1276-1280
21. Uefuji K., Ichikura T., Mochizuki H., and Shinomiya N. Expression of cyclooxygenase-2 protein in gastric adenocarcinoma. J. Surg. Oncol. 69 (1998) 168-172
22. Yamamoto H., Itoh F., Fukushima H., Hinoda Y., and Imai K. Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability. Int. J. Cancer 84 (1999) 400-403
23. Lim H.Y., Joo H.J., Choi J.H., Yi J.W., Yang M.S., Cho D.Y., et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin. Cancer Res. 6 (2000) 519-525
24. Shi H., Xu J.M., Hu N.Z., and Xie H.J. Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World J. Gastroenterol. 9 (2003) 1421-1426
25. Ohno R., Yoshinaga K., Fujita T., Hasegawa K., Iseki H., Tsunozaki H., et al. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer 91 (2001) 1876-1881
26. Blaser M.J., and Parsonnet J. Parasitism by the 'slow' bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. J. Clin. Invest. 94 (1994) 4-8
27. Huang J.Q., Sridhar S., Chen Y., and Hunt R.H. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 114 (1998) 1169-1179
28. Romano M., Ricci V., Memoli A., Tuccillo C., Di Popolo A., Sommi P., et al. Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro. J. Biol. Chem. 273 (1998) 28560-28563
29. Takahashi M., Ota S., Hata Y., Mikami Y., Azuma N., Nakamura T., et al. Hepatocyte growth factor as a key to modulate anti-ulcer action of prostaglandins in stomach. J. Clin. Invest. 98 (1996) 2604-2611
30. Bamba H., Ota S., Kato A., and Matsuzaki F. Nonsteroidal anti-inflammatory drugs may delay the repair of gastric mucosa by suppressing prostaglandin-mediated increase of hepatocyte growth factor production. Biochem. Biophys. Res. Commun. 245 (1998) 567-571
31. Jin L.D., Meng C.L., Han S.H., Ding M.J., Chang T.M., Chan T.K., et al. A study on production of monoclonal anti-bodies using SC-M1 cells as immunogen. Med. Sci. 8 (1987) 17-25
32. Taniguchi T., Kitamura M., Arai K., Iwasaki Y., Yamamoto Y., Igari A., et al. Increase in the circulating level of hepatocyte growth factor in gastric cancer patients. Br. J. Cancer 75 (1997) 673-677
33. Liu S.I., Lui W.Y., Mok K.T., Wu C.W., and Chi C.W. Effect of hepatocyte growth factor on cell cycle and c-met expression in human gastric cancer cells. Anticancer Res. 17 (1997) 3575-3580
34. Hori T., Shibamoto S., Hayakawa M., Takeuchi K., Oku N., Miyazawa K., et al. Stimulation of prostaglandin production by hepatocyte growth factor in human gastric carcinoma cells. Fed. Eur. Biochem. Soc. Lett. 334 (1993) 331-334
35. Giordano S., Di Renzo M.F., Ferracini R., Chiado-Piat L., and Comoglio P.M. P145, a protein with associated tyrosine kinase activity in a human gastric carcinoma cell line. Mol. Cell. Biol. 8 (1988) 3510-3517
36. Ponzetto C., Giordano S., Peverali F., Della Valle G., Abate M.L., Vaula G., et al. C-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. Oncogene 6 (1991) 553-559
37. Kuniyasu H., Yasui W., Kitadai Y., Yokozaki H., Ito H., and Tahara E. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem. Biophys. Res. Commun. 189 (1992) 227-232
38. Lee J.H., Han S.U., Cho H., Jennings B., Gerrard B., Dean M., et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19 (2000) 4947-4953
39. Chiara F., Michieli P., Pugliese L., and Comoglio P.M. Mutations in the met oncogene unveil a 'dual switch' mechanism controlling tyrosine kinase activity. J. Biol. Chem. 278 (2003) 29352-29358
40. Zeng Q., McCauley L.K., and Wang C.Y. Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2. Implication in head and neck squamous cell carcinoma progression. J. Biol. Chem. 277 (2002) 50137-50142
41. Shiota G., and Kawasaki H. Hepatocyte growth factor in trans-genic mice. Int. J. Exp. Pathol. 79 (1998) 267-277